prof - cupharma.cu.edu.eg/.../1314/biography/08_hussein_ammar.docx · web viewname : hussein osman...

Name : Hussein Osman Ammar

Date and Place of Birth: 15.6.1943, Menia, Egypt.

Occupation :

Chairman, Department of Pharmaceutical

Technology, Faculty of Pharmaceutical Sciences

and Pharmaceutical Industries, Future University

in Egypt.

Professor of Pharmaceutical Technology, Department of Pharmaceutical

Technology, National Research Centre, Dokki, Cairo, Egypt.

1948 – 1952 Student, primary school

1952 – 1956 Student, preparatory school

1956 – 1959 Student, secondary school

1959 – 1964 Undergraduate student, Faculty of Pharmacy, Cairo University

1964 – 1965 Pharmacist, Improvement and Development Department,

Chemical Industries Development Inc.

1965 – 1970 Research Associate, Department of Pharmaceutical

Sciences, National Research Centre, Cairo as well as

postgraduate student, Faculty of Pharmacy, Cairo

University.

1968 Obtained M. Pharm. Degree in Pharmacy (Pharmaceutics),

grade excellent, Cairo University, on the basis of a thesis

entitled “A Study of Certain Technological Aspects

Concerning the Stability of Injectable L- Ascorbic Acid

Solutions”

1970 Obtained Ph.D. Degree in Pharmaceutical Sciences

(Pharmaceutics), Cairo University, on the basis of a thesis

entitled “A contribution to the Solubility and Stability of

Riboflavine”

1971 – 1976 Research Staff Member, Department of Pharmaceutical

Sciences, National Research Centre

1976 – 1981 Associate Research Professor, Department of Pharmaceutical

Sciences, National Research Centre, Cairo

1976 – 1980 Teaching, undergraduate students, Pharmaceutical

Technology and Physical Pharmacy, Faculty of Pharmacy,

Assiut University

1976 – 1980 Teaching, Postgraduate Students, Physical Pharmacy,

Faculty of Pharmacy, Assiut University

1976 Postdoctoral Grant, British Royal Society, School of

Pharmacy, Manchester University, U.K.

1981 till now Professor of Pharmaceutical Technology, National Research

Centre

1987 – 2005 Co-chairman, Scientific Permanent Committee of

Pharmaceutical Sciences, National Research Centre

1991 – 1995 Vice-Dean, Pharmaceutical Industries Research Division

National Research Centre

1994 till now Active Member, New YorkAcademy of Sciences

1995 – 1997 Chairman, Department of Pharmaceutical Sciences, National

Research Centre

1995 Scientific Mission, Academy of Sciences, Czech Republic.

1996 Biographee, Who’s Who in the World, 14 th edition.

1997 – 2000 Chairman, Pharmaceutical Industries Research Division,




Suez – Canal University

2001 – 2008 Teaching, postgraduate students, Physical Pharmacy,

Faculty of Pharmacy, Suez – Canal University

2007 Teaching undergraduate students, Pharmaceutics and

Physical Pharmacy, Faculty of Pharmacy, 6th October

University

2007 – 2009 Chairman, Department of Pharmaceutical Technology,


2008 till now Teaching, undergraduate students, Pharmaceutical

Technology and Clinical Pharmacy, Faculty of Pharmacy,

Future University

2012 till now Chairman, Department of Pharmaceutical Technology,

Faculty of Pharmaceutical Sciences and Pharmaceutical

Industries, Future University

Teaching Experience:



Assiut University

1976 – 1980 Teaching, Postgraduate Students, Physical Pharmacy,

Faculty of Pharmacy, Assiut University

2001 till now Teaching, undergraduate students, Pharmaceutical


Suez – Canal University

2001 till now Teaching, postgraduate students, Physical Pharmacy,

Faculty of Pharmacy, Suez – Canal University

2007 Teaching undergraduate students, Pharmaceutics and

Physical Pharmacy, Faculty of Pharmacy, 6th October

University

2008 till now Teaching undergraduate students, Pharmaceutical

Technology and Clinical Pharmacy, Faculty of Pharmacy,

Future University

Participation in Research Projects:

1. Principal Investigator, Research Project financed by Academy of

Scientific Research and Technology, entitled “Studies on the

Bioavailability of Drugs under Local Conditions” (1984 – 1987).

2. Co-principal Investigator, Research Project financed by Academy

of Scientific Research and Technology, entitled “Rubber Articles

for Medical and Pharmaceutical Uses” (1984 – 1987).

3. Consultant, Project no. 4 – 13 – 43, Bilharsiasis National Research

Project, Ministry of Public Health - AID (1991 – 1994).

4. Principal Investigator, Research Project financed by Academy of

Scientific Research and Technology, entitled "A study on the

Bioavailability of Selected Drugs and Reasons for their

Unstability" (1995 – 1998).

5. Principal Investigator, Mega Project financed by National Research

Centre, entitled "Application of Nanotechnology for Delivering

and Improving the Therapeutic Efficacy of Selected Drugs” (2008

– 2010).

6. Principal Investigator, Research Project financed by Ministry of

Trade and Industry and Ministry of Higher Education and State for

Scientific Research, entitled "Development of a drug delivery

system for administration of insulin by oral route" (2008 – 2010).

Participation in International Conferences:

1. Third European Congress of Biopharmaceutics and

Pharmacokinetics, Freiburg, Germany (1987).

2. 47th Congress of Pharmaceutical Sciences of FIP, Amsterdam, The

Netherlands (1987).

3. 5th International Conference on Pharmaceutical Technology, Paris,

France (1989).

4. Fourth European Congress of Biopharmaceutics and

Pharmacokinetics, Geneva, Switzerland (1990).

5. 54th Congress of Pharmaceutical Sciences of FIP, Lisbon, Portugal

(1994).

6. 57th Congress of Pharmaceutical Sciences of FIP, Vancouver,

Canada (1997).

7. 7th Commonwealth Pharmaceutical Association Conference and

Pharmacy Australian Congress, Melbourne, Australia (1999).

8. 60th Congress of Pharmaceutical Sciences of FIP, Vienna, Austria

(2000).

9. 61st Congress of Pharmaceutical Sciences of FIP, Singapore (2001).

10.British Pharmaceutical Conference, Manchester, U.K. (2004).

11.65th Congress of Pharmaceutical Sciences of FIP, Cairo, Egypt

(2005).

12.XIII International Cyclodextrin Symposium, Torino, Italy (2006).

13.British Pharmaceutical Conference, Manchester, U.K. (2006).

14.1st International Conference on Drug Design & Discovery Dubai,

UAE (2008).

15.15thInternational Cyclodextrin Symposium, Vienna, Austria (2010).

Publications: Two patents, 6 patents (under review) and 110 scientific

research papers.

Prizes:1. Awarded the First Class Medal for Science and Arts by President

of the Arab Republic of Egypt (2013).

2. Awarded the Golden Medal of the Academy of Scientific

Research and Technology (2013).

3. Awarded the Appreciation State Prize in the realm of Advanced

Technological Sciences ״Medical Sciences )2010 (״ .

4. Awarded the National Research Centre Prize for Scientific

Appreciation (2009).

5. Awarded the Scopus Award for Scientific Contribution to

Pharmacology (2008).

6. Awarded the National Research Centre Prize for Scientific

Distinction (1994).

Thesis Supervision: 19 M. Pharm. Theses and 10 Ph.D. Theses.

International Activities:1. Active Member, New York Academy of Sciences.

2. Reviewer, Discovery and Innovation.

3. Reviewer, Drug Development and Industrial Pharmacy.

4. Reviewer, Journal of Inclusion Phenomena and Macrocyclic Chemistry.

5. Reviewer, Current Drug Delivery.

6. Reviewer, Expert opinion on Drug Metabolism and Toxicology.

7. Reviewer, Recent Patents on Drug Delivery and Formulation.

8. Reviewer, International Journal of Pharmaceutical Sciences.

9. Reviewer, Asian Journal of Pharmaceutical Sciences.

10.Reviewer, Journal of Carbohydrate Polymers.

11.Reviewer, Journal of Current Nanoscience.

Prof. Dr. Hussein Osman Ammar

List of Publications

I. Scientific papers

(1969)

1. On heavy metal ions contamination from ampoule glass.

Kassem, M.A., Kassem, A.A. and Ammar, H.O., Pharm. ActaHelv.

44, 535.

2. Studies on the stability of injectable L-ascorbic acid solutions.

I. Effect of pH, solvent, light and container.

Kassem, M.A., Kassem, A.A. and Ammar, H.O., ibid. 44, 611.


II. Effect of metal ions and oxygen content of solvent water.


(1972)


III. Effect of metal complexing agents.


(1975)

5. Studies on the stability of injectable solutions of some phenothiazines.

I. Effect of pH and buffer systems.

Ammar, H.O., Salama, H.A. and El-Nimr, A.E.M., Pharmazie 30,

368.

6. Studies on the stability of injectable solutions of some phenothiazines.

II. Effect of chelating agents and antioxidants.

Ammar, H.O., El-Nimr, A.E.M. and Salama, H.A., ibid. 30, 369.

(1976)

7. Stability of injection solutions of vitamin B1.

I. Influence of chelating agents.

Ammar, H.O., ibid. 31, 235.

8. Stability of injection solutions of vitamin B1.

II. Influence of lipoic acid.


9. On the solubilization properties of surfactant-polymer complexes.


10. On the rheology of polyoxyethylene sorbitol lanolin derivatives.

Salama, H.A., Ammar, H.O. and El-Nimr, A.E.M.,

FetteSeifenAnstrichmittel78, 317.

11. On the influence of liquid derivatives of lanolin on the rheology of

hydrocarbon ointmentbases.

Salama, H.A., El-Nimr, A.E.M. and Ammar, H.O., ibid. 78, 319.

(1977)

12. On the dissolution and bioavailability of phenindione.

I. Phenendione tablets.

Ammar, H.O., Kassem, M.A., Salama, H.A. and El-Ridy, M.S., Pharm.

Ind. 39, 171.


II. Dissolution rate of phenindione powder and solid dispersions.

Salama, H.A., Kassem, M.A., Ammar, H.O. and El-Ridy, M.S., ibid.

39, 290.


III. Dissolution and bioavailability of phenindione capsules.

Kassem, M.A., Salama, H.A., Ammar, H.O. and El-Ridy, M.S., ibid.

39, 396.

15. Interaction between thiamine hydrochloride and lipoic acid.

Ammar, H.O. and Salama, H.A., Pharmazie32, 34.

16. Effect of beeswax on the rheological characteristics of soft paraffin.

Salama, H.A and Ammar, H.O., FetteSeifenAnstrichmittel79, 154.

17. A paper chromatographic method for separation and determination of

synephrinein injectable solutions.

El-Nimr, A.E.M., Ammar, H.O. and Salama, H.A., Pharmazie32, 402.

(1979)

18. Rheological studies on Macaloid dispersions.

I. Effect of preservatives.

Salama, H.A. and Ammar, H.O., Pharm. Ind.41, 89.

19. Effect of some hydrotropic agents on the water solubility of

aminophenazone.

Ibrahim, S.A., Ammar, H.O., Kassem, A.A. and Abu- Zaid, S.S.,

Pharmazie34,809.

(1980)

20. On the dissolution of digoxin.

Kassem, M.A., Ammar, H.O., Salama, H.A. and El-Ridy, M.S., Pharm.

Ind.42, 757.

21. Solubilizing benzothiadiazide diuretics by Cetomacrogol 1000.

Ammar, H.O. and Salama, H.A., ibid. 42, 849.

22. Solubility of chlorothiazide and hydrochlorothiazide in mixed aqueous

solvent system

Ibrahim, S. A., Ammar, H.O. and El-Faham, T.H., Proc. 2nd Intern.

Pharm. Conf. Pharm. Technol., Paris, France, June 3-5.

23. Interaction of aromatic monocarboxylic acid derivatives with

amidopyrine.

Ammar, H.O., Ibrahim, S.A., Kassem, A.A. and Abu- Zaid, S. S.,

Pharm. Ind. 42, 1312.

24. Studies on some factors affecting stability of isoniazid solutions.

I. Effect of pH - value and buffer system.

Ibrahim, S.A., Ammar, H.O. and Abd El- Mohsen, M.G., Bull. Pharm.

Sci., AssiutUniversity3, 25.

(1981)

25. Effect of alcohols on the rheological characteristics of Macloid

dispersions.

Salama, H.A. and Ammar, H.O., Pharmazie36, 15.

26. Effect of polyvinylpyrrolidone on the rheological characteristics of

Macloid dispersions.

Salama, H.A. and Ammar, H.O., ibid. 36, 262.

27. Interaction between bendroflumethiazide and caffeine.

Ammar, H.O. and Salama, H.A., ibid. 43, 265.

28. Effect of sodium salts of toluic acids on the water solubility of

riboflavine.

Ammar, H.O. and Salama, H.A., Pharm. Ind.43, 194.

29. Interaction of chlorothiazide and hydrochlorothiazide with certain

amides, imides andxanthines.

Ammar, H.O., Ibrahim, S.A. and El- Faham, T.H., ibid. 43, 292.

30. On the dissolution of chlorothiazide powders and solid dispersions.

Salama, H.A., Ammar, H.O., Kassem, M.A. and El-Ridy, M. S., ibid. 43,

1242.

(1982)

31. Effect of aromatic hydrotropes on the solubility of some

benzothiadiazines.

Ammar, H.O., Ibrahim, S.A. and El- Faham, T.H., Pharmazie37, 36.

32. Effect of chelating agents on the stability of inectable isoniazid

solutions.

Ibrahim, S.A., Ammar, H.O. and Abd El- Mohsen, M.G., ibid. 37, 272.

33. On the dissolution of chlorothiazide and hydrochlorothiazide tablets and

capsules.

Ammar, H.O., Kassem, M.A., Salama, H.A. and El-Ridy, M.S., Bull.

Nat. Res. Centre, Egypt7, 75.

34. On the dissolution of hydrochlorothiazide powders and solid

dispersions.

Kassem, M.A., Salama, H.A., Ammar, H.O. and El-Ridy, M.S., Pharm.

Ind.44, 1186.

35. Complex formation between antihistaminic drugs and caffeine.

Mattha, A. G., Ammar, H.O., Abdel-Samie, M., El-Nahhas, S.A. and

Kassem, M.A.,

Pharm. Acta.Helv.57, 268.

(1983)

36. Interaction of pheothiazines and caffeine.

I. Complex formation.

Ammar, H.O., Mattha, A.G., Abdel-Samie, M., El-Nahhas, S.A. and

Kassem, M.A.,ibid. 58, 23.

37. Interaction of pheothiazines and caffeine.

II. Effect of complexation with caffeine on the stability and in-vitro

transport of phenohiazines.

Abdel- Samie, M., Ammar, H.O., Mattha, A.G., El-Nahhas, S.A. and

Kassem, M.A., ibid. 58, 28.

(1989)

38. Solubilizing of glucocorticoids with cetomacrogol.

Ammar, H.O. and Omar , S.M., Pharm.Ind.51, 1450.

(1991)

39. Interaction of pheothiazines with xanthines.

I. Interaction of pheothiazineswith caffeine.

Ammar, H.O., Elmahrouk, G., Omar, S.M., El-Nahhas, S.A. and

Kassem, M.A., ibid. 53, 786.


II. Interaction of phenothiazineswith theophylline.

Elmahrouk, G., Ammar, H.O., Omar, S. M., El-Nahhas, S.A. and

Kassem, M.A., ibid.53, 868.


III. Effect of complexation with xanthines on the bioavailability of

chlorpromazine.

Ammar, H.O., Omar, S. M., El-Nahhas, S.A. and Kassem, M.A., ibid.

53, 959.

(1992)

42. Interaction of glucocorticoids with xanthines.

Ammar, H.O., El-Nahhas, S. A., Omar, S. M. and Khalil, R. M.,

Egypt.J. Pharm. Sci.33, 981.

(1993)

43. Discrepancy among dissolution rates of commercial tablets as a

function of dissolution method.

I. Prednisolone tablets.

Ammar, H.O., Khalil, R. M. and Omar, S. M., Pharmazie48, 57.



II. Paracetamol tablets.

Ammar, H.O. and Khalil, R.M., ibid. 48, 129.



III. In vitro/in vivo correlation for paracetamol tablets.


46. Effect of aromatic hydrotropes on the solubility of allopurinol.

I. Effect of sodium salts of hydroxy and amino derivatives of benzoic

acid.

Ammar, H.O. and El-Nahhas, S.A., ibid. 48, 436.


II. Effect of nicotinamide and sodium salts of benzoic, naphthoic and

nicotinic acids.



III. Effect of sodium salts of toluic acids.


49. Effect of aromatic hydrotropes on the solubility of phenacetin.


acid.


50. Effect of aromatic hydrotropes on the solubility of phenacetin.


nicotinic acids.

Ammar, H.O., Omar, S.M. and Khalil, R. M., ibid. 48, 845.



IV. Chloropromazine hydrochloride tablets.

Ammar, H.O., Omar, S.M. and Khalil, R. M., ibid. 48, 927.



V. In vitro/in vivo correlation for chlorpromazine hydrochloride

tablets.

Ammar, H.O., Khalil, R.M. and Omar, S.M., ibid. 48, 932.

(1994)

53. Evaluation of antischistosomal effect of praziquantel in a liposomal

delivery system.

Ammar, H.O., El- Ridy, M.S., Ghorab, M. and Ghorab, M.M., Int. J.

Pharm. 103, 237.

54. Interaction of allopurinol with phenylephrine and certain analgesics.

Ammar, H.O., El-Nahhas, S.A., Omar, S. M. and Khalil, R.M., J.

Drug Res., Egypt 21, 65.

55. Solubilization ofbromhexine hydrochloride by non -ionic surfactants.

Ammar, H.O. and El-Nahhas, S.A., Pharmazie49, 583.

56. Effect of aromatic hydrotropes on the solubility of carbamazepine.


acid.

Ammar, H.O. and Omar, S.M., Egypt. J. Pharm. Sci. 35 ,189.

57. Effect of aromatic hydrotropes on the solubility of carbamazepine.


nicotinic acids.

Ammar, H.O. and Omar, S.M., ibid. 35, 209.

58. Solubilization of carbamazepine hydrochloride by non -ionic

surfactants.

Ammar, H.O. and Omar, S.M. ,Pharmazie49, 746.

59. Solubiliztion of allopurinol with methyl xanthines.

Ammar, H.O., El-Nahhas, S.A., Khalil, R.M. and Omar, S.M. ibid.

49,839.

(1995)

60. Improvement of some pharmaceutical properties of drugs by

cyclodextrin complexation.

I. Allopurinol.

Ammar, H.O. and El-Nahhas, S.A., ibid.50, 49.



II. Colchicine.

Ammar, H.O. and El-Nahhas, S.A., ibid.50, 269.



III. Bromhexine hydrochloride.




IV. Chlorpromazine hydrochloride.

Ammar, H.O., Ghorab, M., El-Nahhas, S.A., Omar, S.M. and Ghorab,

M.M., ibid. 50, 805.

(1996)

64. Effect of aromatic hydrotropes on the solubility of oxamniquine.


acid.




V. Theophylline.


M. M., ibid. 51, 42.



VI. Ampicillin.

Ammar, H.O., El-Nahhas, S.A. and Ghorab, M.M., ibid. 51, 568.



VI. Rifampicin.


68. Effect of aromatic hydrotropes on the solubility of oxamniquine.

II. Effect of nicotinamide and sodium salts of benzoic, naphthoic,

nicotinic and isonictinic acids.


69. Solubilization of certain analgesics by Cetomacrogol 1000.

Ammar, H.O. and Khalil, R.M., Egypt. J. Pharm. Sci. 37, 261.

70. Interaction of dicumarol with β- cyclodextrin.


M.M., ibid.37, 431.

71. Interaction of hydrochlorothiazide with β- cyclodextrin.


M.M., ibid. 37, 445.

(1997)



VII. Aspirin.

Ammar, H.O., El-Nahhas, S.A., Emara, L.H., Ghorab, M.M. and Salama,

H.A., Pharmazie52, 145.



VII. Trimethoprim.

Ammar, H.O., El-Nahhas, S.A. and Emara, L.H., ibid. 52, 376.

74. Improvement of the biological performance of oral anticoagulant

drugs.

I. Warfarin.

Ammar, H.O., Ghorab, M., El-Nahhas, S.A. and Makram, T.S., ibid.

52, 627.

75. Improvement of the biological performance of oral anticoagulant

drugs.

II. Dicumarol

Ammar, H.O., Ghorab. M., El-Nahhas, S.A. and Makram, T.S., ibid.

52, 727.

76. Preparation and evaluation of sustained – release solid dispersions of

drugs with Eudragit polymers.

Ammar, H.O. and Khalil, R.M., Drug Devel. Ind. Pharm. 23, 1043.

77. Interaction of oral anticoagulants with methyl xanthines.

Ammar, H.O., Ghorab, M., El-Nahhas, S.A. and Makram, T.S.,

Pharmazie52, 946.

78. Dissolution rate as a predictory tool for assessing comparative

bioavailability of generic ampicillin capsules.

Ammar, H.O., El-Nahhas, S.A. and Khalil, R.M., Egypt.J. Pharm. Sci.

38, 527.

(1998)

79. Cyclodextrin in acetazolamide eye drops formulations.

Ammar, H.O., El- Nahhas, S.A. and Khalil, R.M., Pharmazie53, 559.

80. Liposomal delivery systems in hydrocortisone eye drops formulation.

Salama, H.A., Ammar, H.O. and Khalil, R. M., Egypt.J. Pharm. Sci.

39, 19.

81. Liposomal delivery systems in timolol maleate eye drops formulation.

Salama, H. A., Ammar, H.O. and Khalil, R. M., ibid. 39, 109.

(1999)

82. Inclusion complexation of furosemide in cyclodextrins.

I. Effect of cyclodextrins on the physicochemical characteristics of

furosemide.

Ammar, H.O., Ghorab, M., Emara, L.H., El- Nahhas, S.A. and Makram,

T.S., Pharmazie54, 142.

83. Inclusion complexation of furosemide in cyclodextrins.

II. Implication on bioavailability.

Ammar, H.O., Ghorab, M., Emara, L.H., El- Nahhas, S.A. and Makram,

T.S., ibid.,54, 207.

(2000)

84. Design of slow – release furosemide.

Ammar, H.O., Ghorab, M., El- Nahhas, S.A. and Makram, T.S.,

Pharmacy World Congress 2000, Vienna, Austria 26 – 31 August.

(2001)

85. Design of dexamethazone eye drops with prolonged effect.

Ammar, H.O., Salama, H.A., Ghorab, M., El- Nahhas, S.A. and

Elmotasem, H., Pharmacy World Congress 2001, Singapore 1 – 6

September.

(2004)

86. A transdermal delivery system for glipizide.

Ammar, H.O., Salama, H.A., Ghorab, M., El- Nahhas, S.A. and

Elmotasem, H., J. Pharm. Pharmacol.56, S - 41.

(2005)

87. Design and evaluation of prednisolone acetate eye drops with

prolonged effect.

Ammar, H.O., Salama, H.A., Ghorab, M., El - Nahhas, S.A. and

Elmotasem, H., Egypt.J. Pharm. Sci. 46, 9.

88. A transdermal delivery system for aspirin as an antithrombotic drug.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A. and Kamel, R., British

Pharmaceutical Conference, Manchester, U.K.

(2006)

89.Formulation and biological evaluation ofglimepiride–cyclodextrin–

polymer systems.

Ammar, H.O.,Salama, H.A.,Ghorab, M. and Mahmoud,A.A., Int. J.

Pharm.309,129.

90. Implication of inclusion complexation of glimepiride incyclodextrin–

polymer systems on its dissolution,stability and therapeutic efficacy.

Ammar, H.O.,Salama, H.A.,Ghorab, M. and Mahmoud,A.A.,

ibid.,320, 53.

91. A Transdermal Delivery System for Glipizide.

Ammar, H.O., Salama, H.A., Ghorab, M., El –Nahhas,

S.A.andElmotasem, H., Current Drug Delivery, 3, 333.

92. Design of a transdermal delivery system for aspirin as an

antithrombotic drug.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A.andKamel, R., Int. J.

Pharm.,327, 81.

(2007)

93. Inclusion Complexation of Glimepiride in Dimethyl-β-Cyclodextrin.

Ammar, H.O., Salama, H.A., Ghorab, M. and Mahmoud, A.A., Asian

Journal of Pharmaceutical Sciences, 2, 44.

94. Physicochemical and biological evaluation of chemical penetration

enhancers for transdermal delivery of aspirin.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A.andKamel, R., ibid.,2,

96.

95. Nanoemulsions for delivering warfarin transdermally.

Ammar, H.O., Salama, H.A., Ghorab, M., El - Nahhas, S.A. and El

Feky, G.S., 1st Conferance on Material Sciences and

Nanonotechnology “Future Challenges”,National Research Centre,

Cairo, Egypt.

96. Extended release of tramadol hydrochloride using polymeric matrix

system via transdermal route.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A. and Kamel, R., 1st

Conferance on Material Sciences and Nanonotechnology “Future

Challenges”,National Research Centre, Cairo, Egypt.

(2008)

97. Design and evaluation of chitosan films for transdermal delivery of

glimepiride.

Ammar, H.O.,Salama, H.A., El-Nahhas, S.A., and Elmotasem, H.,

Current Drug Delivery,5, 290.

98. Polymeric matrix system for transdermal delivery of tramadol

hydrochloride.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A. andKamel, R., 1st

International Conference on Drug Design & Discovery, February 4-7,

Dubai, UAE.

(2009)

99. Polymeric matrix system for prolonged delivery of tramadol

hydrochloride, Part I: Physicochemical evaluation.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A. andKamel, R., AAPS

PharmSciTech, 10, 7.

100. Polymeric matrix system for prolonged delivery of tramadol

hydrochloride, Part II: Biological evaluation.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A. andKamel, R.,

ibid.10, 1065.

101. Nanoemulsion as a potential ophthalmic delivery system for

dorzolamide hydrochloride.

Ammar, H.O., Salama, H.A., Ghorab, M. andMahmoud, A.A., AAPS

PharmSciTech, 10, 808.

(2010)

102. Development of dorzolamide hydrochloride in situ gel nanoemulsion

for ocular delivery.

Ammar, H.O., Salama, H.A., Ghorab, M. and Mahmoud, A.A., Drug

Dev. Ind. Pharm., 36, 1330.

(2011)

103.Proniosomes as a carrier system for transdermal delivery of tenoxicam.

Ammar, H.O., Ghorab, M., EL - Nahhas, S.A.and Higazy, I.M., Int. J.

Pharm., 405, 142.

104.Preparation and evaluation of hydrogels as a vehicle for topical delivery

of lornoxicam.

Ammar, H.O., Ghorab, M. and Mahmoud, A.A., Makram, T.S. and

Noshi, S.H., Int. J. Drug Formulation & Research, 2.

(2012)

105. Chitosan /cyclodextrinnaoparticles as drug delivery system.

Ammar, H.O., El-Nahhas, S.A., Ghorab, M.M. andSalama,A.H., J. Incl.

Phenom. Macrocycl. Chem., 136, 127.

106. Novel microemulsions as transdermal delivery systems for enhanced

efficacy of fluoxetine hydrochloride.

Ammar, H.O., Badawi, A.A, Mostafa, D.M and Abou-Taleb, S.A.,

Asian J. of Pharmaceutical Sciences and Research 2 , issue 4.

107. Topical liquid crystalline gel containing lornoxicam/cyclodextrin

complex.


Noshi, S.H., J. Incl. Phenom. Macrocycl. Chem., 73, 161.

108. Rice bran oil: preparation and evaluation of novel liquisolid and

semisolid formulations.

Ammar, H.O., Al-Okbi, S.Y., Mostafa, D.M. and Helal, A.M., Int. J.

Pharm. Compounding, 16, 516.

(2013)

109. Host-guest system of etodolac in native and modified β-cyclodextrins:

preparation and physicochemical characterization.

Ammar, H.O., Ghorab, M., Mostafa, D.M., Makram, T.S. and Ali,

R.M., J. Incl Phenom Macrocycl Chem., 77, 121-134.

110. Rapid pain relief using transdermal film forming polymeric solution of

ketorolac.


Ghoneim, A.M., Pharm. Dev. Technol., 18, 1005-16.

II. Patents

1. A new method for preparing stable injectable L- ascorbic acid

solutions.

Kassem, M.A. and Ammar, H.O., Egypt. Pat. 10032 (1969).

2. A method for preparing sustained release insulin beads.

Ammar, H.O., El- Ridy, M. S., Abdallah, N.A., Soror, M.H., Gamal,

A.M., Ezz, H.A. and Shaalan, H.F., Egypt. Pat. 23187 (2004).

3. Investigation of the transdermal bioavailability of aspirin.

Ammar, H.O., Ghorab M., El – Nahhas, S.A. and Kamel, R., ibid.

Appl. 2005030122, March 14th, 2005.

4. Innovation of new pharmaceutical formulation of warfarin for

transdermal use.

Ammar, H.O., Salama, H.A., Ghorab, M., El – Nahhas, S.A. and El –

Feky, G.S., ibid. Appl. 2005030145, March 22nd, 2005.

5. Innovation of new pharmaceutical formulation for glimepiride tablets

characterized by high therapeutic efficacy.

Ammar, H.O., Salama, H.A., Ghorab, M. and Mahmoud, A.A., ibid.

Appl. 2005050248, May 22nd, 2005.

6. Innovation of a transdermal delivery system for tramadol.

Ammar, H.O., Ghorab M., El – Nahhas, S.A. and Kamel, R., Egypt.

Pat. Appl. 2006070361, January 3rd, 2006.

7. Innovation of a new gelatine product from wastes of birds for food and

pharmaceutical industries.

Ammar, H.O., Mostafa, E.M., Egypt. Pat. Appl. 2007.

8. Innovation of a new formulation for dorzolamide hydrochloride eye

drops characterized by high therapeutic efficacy.

Ammar, H.O., Salama, H.A., Ghorab and Mahmoud, A.A., Egypt.

Pat., Appl. 20080400666, April 4th, 2008.

prof - cupharma.cu.edu.eg/.../1314/biography/08_hussein_ammar.docx · web viewname : hussein osman...

Documents